deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03532217

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Sponsor: Bavarian Nordic

Conditions Metastatic Hormone-Sensitive Prostate Cancer
Interventions Fecal samples Ipilimumab Leukapheresis Neoantigen DNA vaccine Nivolumab PROSTVAC-F PROSTVAC-V Peripheral blood TriGrid Delivery System Tumor biopsy
Updated 20 times since 2018 Last updated: Aug 3, 2022 Started: Sep 14, 2018 Primary completion: Apr 1, 2022 Completion: Jul 25, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03532217, this PHASE1 trial focuses on Metastatic Hormone-Sensitive Prostate Cancer and remains completed. Sponsored by Bavarian Nordic, it has been updated 20 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Jun 2019 · 5 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 15 earlier versions

  1. Feb 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Mar 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  6. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1

  7. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  8. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  9. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  10. Feb 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  11. Oct 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  12. Jun 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  13. Jan 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  14. Oct 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  15. Jun 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bavarian Nordic
  • Bristol-Myers Squibb
  • Prostate Cancer Foundation
  • The Foundation for Barnes-Jewish Hospital
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations